{
  "docId": "019de075-c1ce-7016-922a-ee59c26b52e2",
  "docSlug": "7a9033616f2f52a3ff84a89721dd4a41",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 23,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a molecular pathway diagram and a Western blot image as evidence.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/8",
  "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2",
  "deckJsonHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2.json",
  "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.52,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "callout",
      "text": "NXP800 activates GCN2 >> GCN2 activates the Integrated Stress Response (ISR) >> ISR activation causes a translational switch which includes downregulation of HSF1-regulated genes",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46a11e1f-0574-431b-a528-c1999afe796b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.36,
        "x": 0.61,
        "y": 0.17
      },
      "kind": "callout",
      "text": "ATF4 was induced in vivo in SKOV3 xenografts; ATF4 Validated as biomarker for preclinical activity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc3192e8-de43-445f-a652-cf2cf84f2aeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.36,
        "x": 0.61,
        "y": 0.88
      },
      "kind": "callout",
      "text": "ATF4 induction observed in patient samples in the phase 1a",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc51feb3-34c1-47d9-bea9-26713727bdc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.52,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "diagram",
      "text": "Molecular pathway diagram showing NXP800, GCN2, eIF2a, and ATF4",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01e432de-127a-48fa-9b0f-76519091da9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.26,
        "x": 0.66,
        "y": 0.31
      },
      "kind": "image",
      "text": "Western blot showing ATF4 induction",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01421a34-7803-4d95-b314-8a5d4a91c4e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.66,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "Clarke et al, ENA 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4dff9a7-2de9-4ce5-bfbc-ec3b5d4f7d7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXP800 Mechanism of Action",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7668037c-6f6b-4e92-a2f4-1a1484563958",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "NXP800 is a GCN2 kinase activator",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e234f46-55f1-4cf4-abfb-6f4497675a11",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "24dde07a-12e9-4648-b7de-c09ec1d6fa37",
      "evidence": "The diagram maps the step-by-step biological activation process.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb",
      "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline",
      "position": 0,
      "objective": "Highlight the cost of inaction in oncology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac",
      "evidence": "The document presents data on the potential of NXP800 and NXP900",
      "position": 1,
      "objective": "Present Nuvectis Pharma's solution as a quick win and big bet",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}